Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-move multicentre case control studies at primary care and hospital levels in Europe

Eurosurveillance

Volumn 22, Issue 7, 2017, Pages

  Kissling, E ^a   Rondy, M ^a   Kaić, Bernard ^b   Horváth, Judit Kriszttina ^c   Ferenczi, Annmária ^c   Oroszi, Beatrix ^c   Vizler, Zita ^d   Hercegh, Éva ^c   Szala, Bálin ^c   Alfonsi, Valeria ^e   Bella, Antonino ^e   Paradowska Stankiewicz, Iwona ^f   Brydak, Lidia ^f   Nunes, Baltazar ^g   Machado, Ausenda ^g   Rodrigues, Ana Paula ^g   Gomez, Verónica ^g   Kislaya, Irina ^g   Uva, Mafalda Sousa ^g   Guiomar, Raquel ^g   Pechirra, Pedro ^g   Cristóvao, Paula ^g   Conde, Patrícia ^g   Costa, Ines ^g   Pitigoi, Daniela ^h   Lupulescu, Emilia ⁱ   Ivanciuc, Alina Elena ⁱ   Lazar, Mihaela ⁱ   Cherciu, Carmen Maria ⁱ   Larrauri, Amparo ^j   Gherasim, Alin ^k   Pozo, Francisco ^k,l   Comas, Luis García ^m   Carril, Fernando Gonzalez ⁿ   Castilla, Jesus ^o   Quinones, Carmen ^p   Giménez, Jaume ^q   Castrillejo, Daniel ^r   Amores, Madalen Oribe ^s   Falchi, Alessandra ^t   Vilcu, Ana Maria ^u   Souty, Cécile ^u   Blanchon, Thierry ^u   Behillil, Sylvie ^v   Enouf, Vincent ^v   Cité, Sornonne Paris ^v   Lina, Bruno ^w,x   Valette, Martine ^w   Reuss, Anicka ^y   Buda, Silke ^y   Prahm, Kerstin ^y   Wedde, Marianne ^y   Martin, Maria ^y   Biere, Barbara ^y   O’Donnell, Joan ^z   Domegan, Lisa ^z   Kelly, Anita ^z   Joyce, Michael ^aa   Collins, Claire ^aa   De Gascun, Cillian ^ab   Connell, Jeff ^ab   Tuite, Grainne ^ab   Duffy, Margaret ^ab   Moran, Joanne ^ab   Hogg, Bridget ^ab   Dunford, Linda ^ab   Brytting, Mia ^ac   Zakikhany, Katherina ^ac   De Lange, Marit ^ad   Donker, G ^ae   Johansen, Kari ^af   Penttinen, Pasi ^af   Syrjänen, Ritva ^ag   Nohynek, Hanna ^ag   Haveri, Anu ^ag   Launay, Odile ^t,ah   Galtier, Florence ^t,ai   Vanems, Philippe ^t,aj,ak,al   Lainé, Fabrice ^t,am   Lenzi, Nezha ^t   Antmann, Katalin ^an   Nagy, Kamilla ^ao   Gefenaite, Giedre ^ap   Kuliešė, Monika ^ap   Mickiene, Aukse ^ap   Jancoriene, Ligita ^aq   Zablockiene, Birute ^aq   Damuleviciene, Gyte ^ap   Grimalauskaite, Rita ^ap   Bagdonas, Alfredas ^ap   Casado, Itziar ^o   Díaz González, Jorge ^j,o   Castilla, Jesús ^j,o   Nitescu, Maria ^ar   Ceausu, Emanoil ^as   Bejan, Codrina ^at   Marbus, Sierk ^au   more..

^a EPICONCEPT   (France)

^b Croatian Institute of Public Health   (Croatia)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d Office of the Chief Medical Officer   (Hungary)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f NATIONAL MEDICINES INSTITUTE   (Poland)

^g NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^h CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ National Institute for Research Cantacuzino   (Romania)

^j CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m National Institute for Research Cantacuzino ^*  (Spain)

ⁿ Gobierno del País Vasco   (Spain)

^o Recinto de Complejo Hospitalario de Navarra   (Spain)

^p Dirección General de Salud Pública y Consumo de La Rioja   (Spain)

^q Mallorca   (Spain)

^r Hospital Comarcal de Melilla   (Spain)

^s Dirección General de Salud Pública   (Spain)

^t INSERM   (France)

^u SORBONNE UNIVERSITÉ   (France)

^v INSTITUT PASTEUR   (France)

^w Hospices Civils de Lyon   (France)

^x UNIVERSITÉ DE LYON   (France)

^y ROBERT KOCH INSTITUTE   (Germany)

^z HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^aa IRISH COLLEGE OF GENERAL PRACTITIONERS   (Ireland)

^ab UNIVERSITY COLLEGE DUBLIN   (Ireland)

^ac SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^ad National Institute for Public Health and the Environment (RIVM)   (Sweden)

^ae Netherlands Institute for Health Services Research (NIVEL)   (Sweden)

^af EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^ag NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^ah ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^ai HÔPITAL SAINT ELOI   (France)

^aj EDOUARD HERRIOT HOSPITAL   (France)

^ak CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^al UNIVERSITÉ DE LYON   (France)

^am RENNES UNIVERSITY HOSPITAL   (France)

^an SEMMELWEIS UNIVERSITY   (Hungary)

^ao UNIVERSITY OF SZEGED   (Hungary)

^ap LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^aq VILNIUS UNIVERSITY   (Lithuania)

^ar Matei Bals Hospital   (Romania)

^as Department of Dermatology   (Romania)

^at Sfanta Parascheva Hospital   (Romania)

^au NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; EUROPE; FEMALE; FEVER; GENERAL PRACTITIONER; HOSPITAL PATIENT; HUMAN; INFANT; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; NEWBORN; PEDIATRICIAN; PRIMARY MEDICAL CARE; PROPHYLAXIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEQUENCE ANALYSIS; VERY ELDERLY; VIRAL RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; EUROPEAN UNION; HEALTH SURVEY; HOSPITAL; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; OUTCOME ASSESSMENT; PANDEMICS; PRESCHOOL CHILD; PRIMARY HEALTH CARE; SEASON; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EUROPE; EUROPEAN UNION; FEMALE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANDEMICS; POPULATION SURVEILLANCE; PRIMARY HEALTH CARE; SEASONS; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 85014105621     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.7.30464     Document Type: Article

References (15)

1. European Centre for Disease Prevention and Control (ECDC). Risk assessment of seasonal influenza, EU/EEA, 2016-2017 - Update 25 January 2017 Stockholm: ECDC; 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/Risk-assessment-seasonal-influenza-2016-2017-update.pdf
2. European monitoring of excess mortality for public health action (EuroMOMO). Mortality monitoring in Europe mortality bulletin, week 1-2017. Copenhagen: EuroMOMO. [Accessed 20 Jan 2017]. Available from: http://www.euromomo.eu/
3. Säsongstatistik för influensa 2016/2017 [Season statistics for influenza 2016/2017]. Stockholm: Smittskydd Stockholm. [Accessed: 4 Feb 2017]. Swedish. Available from: http://www.vardgivarguiden.se/behandlingsstod/smittskydd/dokument/statistik/influensa/sasongen-2016-2017/
4. Ajantasainen influenssakatsaus. [Real-time influenza report]. Helsinki: National Institute for Health and Welfare (THL). [Accessed: 14 Feb 2017]. Finnish. Available from: https://www.thl.fi/fi/web/infektiotaudit/taudit-ja-mikrobit/virustaudit/influenssa/ajantasainen-influenssakatsaus
5. Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, et al., European hospital IVE network. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2):21011. DOI: 10.2807/1560-7917.ES2015.20.2.21011 PMID: 25613779
6. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):20701. DOI: 10.2807/1560-7917.ES2014.19.6.20701 PMID: 24556348
7. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al., Joan O´Donell, I-MOVE multicentre case-control team. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.Euro Surveill. 2016;21(7):30139. DOI: 10.2807/1560-7917.ES.2016.21.7.30139 PMID: 26924024
8. European Centre for Disease Prevention and Control (ECDC). Protocol for case control studies to measure pandemic and seasonal vaccine effectiveness in the European Union and European Economic Area. Stockholm: ECDC; 2009. Available from: http://ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf
9. EpiConcept. Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Paris: I-MOVE+. [Accessed: 5 Feb 2017]. Available from: https://drive.google.com/a/epiconcept.fr/file/d/0B54XpZN4SY65QXFqQThQNEQ5cmM/view
10. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter A, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460. DOI: 10.2807/1560-7917.ES.2017.22.6.30460
11. Kissling E, Valenciano M, I-MOVE Case-Control Studies Team. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill. 2012;17(15):20146.PMID: 22516046
12. Valenciano M, Kissling E, I-MOVE Case-Control Study Team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):3.PMID: 23449183
13. World Health Organization (WHO). WHO consultation and information meeting on the composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Geneva: WHO. [Accessed: 5 Feb 2017]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/consultation201702/en/
14. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al., I-MOVE case-control study team. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16):30201. DOI: 10.2807/1560-7917. ES.2016.21.16.30201 PMID: 27124420
15. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8 PMID: 27061888